The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
SARATOGA, N.Y. (WNYT)- Regeneron says they have purchased the sprawling former Quad Graphics site on Duplainville Road in ...
Regeneron has officially purchased the site of the Quad Graphics building, according to local officials. The Albany Business ...
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating ...
Regeneron REGN1.83%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.74%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of their ...